Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

ation (2006: $5.4 million) which included a $4.6 million cumulative catch up charge in respect of 2005 awards, see page 18.

1 Upfront and milestone payments in 2007 were made to Renovo $75.0 million, Amicus $50.0 million, Alba $25.0 million and Noven $5.9 million.

2 Upfront and milestone payments in 2006 were made to New River $50.0 million, Duramed Pharmaceuticals Inc. ("Duramed") $25.0 million and Warren Pharmaceuticals Inc ("Warren") $5.5 million.

Selling, general and administrative

% of product % of product

2007 sales 2006 sales

_________ _________ _________ _________

SG&A (US GAAP) 1,041.7 48% 835.4 54%

Legal settlements (net) (17.0) -

FAS123R (1) (52.7) (34.4)

_________ _________

Non GAAP SG&A 972.0 45% 801.0 52%

(1) Includes 2005 option catch up charge SG&A expenses increased to $1,041.7 million for the year to December 31, 2007 from $835.4 million in the year to December 31, 2006, an increase of 25% which was substantially less than the product sales increase of 41%.

The increase in SG&A expenses included the impact of the following:

- An increase in the ADHD sales force to promote VYVANSE;

- The cost of the new GI sales force in the US;

- The advertising, promotional and marketing spend to support the launches of VYVANSE, LIALDA and ELAPRASE; and

- A net charge of $17.0 million in respect of legal settlements, being a charge of $27.0 million for settlement of the TKT purported securities fraud class action shareholder suit partially offset by a $10.0 million release of existing legal provisions.

Excluding the net charge for legal settlements and s
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014  CSSi ( www.CSSiEnroll.com ), the leader ... industry, is pleased to announce its participation in ... October.  President Chris Trizna will be ... Clinical Trials New England conference sponsored by Arena ... annual Site Solutions Summit sponsored by the Society ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , ... , a leader in synthetic biology, and ... drug manufacturer by volume in the U.S., today ... Collaboration (ECC) for a target active pharmaceutical ingredient ... goal of the collaboration is to develop a ...
(Date:10/1/2014)... What: , Cambridge Semantics, the leading provider ... technology, today announced its participation in the 2014 Big ... Data solutions provide semantic linkage and meaning to Big ... and manage diverse data. Ben Szekely, vice president and ... a “life sciences data lake” and an approach for ...
(Date:10/1/2014)... 1, 2014  Discovery Laboratories, Inc. (Nasdaq: DSCO) ... a Phase II Small Business Innovation Research Grant ... the National Institute of Allergy and Infectious Diseases ... to support the development of the Company,s aerosolized ... to mitigate acute and chronic/late-phase radiation-induced lung injury. ...
Breaking Biology Technology:Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 2Patient Recruitment Expert CSSi to be Featured at Upcoming Industry Events 3Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Cambridge Semantics to Present ‘A Useful Approach to Big Data’ at 2014 Big Data Leaders Forum 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Boston Scientific Corporation (NYSE: BSX ) today ... and Drug Administration (FDA) to market its TAXUS(R) Liberte ... deliverable, next-generation drug-eluting stent (DES) specifically designed for treating ... in vessels as small as 2.25 mm in diameter ...
... Network Sciences, Inc. (GNS) today announced that it ... University of California San Francisco Cancer ... drug development across several therapeutic areas. This collaboration ... of UCSF with the computational expertise and supercomputer-driven ...
... Cell Institute (RSCI) today announced its 2009 Science Advisory Board. Once ... world-leader and has a world-first to his credit. , ... Dallas, Texas ... http://www.RepairStemCells.org , a Dallas, Texas-based stem cell global public affairs organization founded ...
Cached Biology Technology:FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results 2RSCI Announces World-Leading Stem Cell Science Advisory Board 2RSCI Announces World-Leading Stem Cell Science Advisory Board 3
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the largest international study to date into the genetic basis ... disease and provide evidence that large-scale genetic studies can assist ... as rheumatoid arthritis. The study, conducted by Dr. Robert ... Institute in the USA and Dr. Yukinori Okada from the ...
... a recent study published in the Neural Regeneration ... Li and team from Zhongshan School of Medicine, Sun ... BACE1, the key enzyme in amyloid beta protein (Aβ) ... construct a short hairpin (shRNA) expression plasmid against the ...
... is in ideal cardiovascular health, according to the new CANHEART ... CMAJ ( Canadian Medical Association Journal ). Cardiovascular ... leading cause of death in Canada. "A large proportion ... trend has not changed in the past decade," says senior ...
Cached Biology News:Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 3
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: